Middle-aged women are frequent visitors in headache clinics. We investigated the differences in headache characteristics of middle-aged women (aged 40–54 years) according to their menopausal status. In total, 229 women were divided into the following three groups: premenopausal (n = 78), perimenopausal (n = 69), and postmenopausal (n = 82). The prevalence of tension-type headaches was higher in the peri- and postmenopausal groups than in the premenopausal group (p < 0.05), whereas the prevalence of migraines was similar across the three groups. The proportion of patients with a short duration of headache history (<6 months) was significantly higher in the perimenopausal group (40.6%) than in the premenopausal (12.8%) or postmenopausal (17.1%) groups (p < 0.01). Analysis of headaches in perimenopausal patients who did not receive exogenous hormone treatment (n = 61) showed that current headaches were reported as new-onset headaches by 47.5% of subjects, as aggravations of prior headaches by 34.4% of subjects, or as unchanged from prior headaches in 18.0% of subjects. This study shows that the prevalence of tension-type headaches is different between menopausal periods, whereas the prevalence of migraines is not changed. Perimenopausal women tended to experience relatively more tension-type headaches and visited the hospital mainly due to new-onset headaches or aggravated headaches.

1.
Li C, Borgfeldt C, Samsioe G, Lidfeldt J, Nerbrand C: Background factors influencing somatic and psychological symptoms in middle-age women with different hormonal status a population-based study of Swedish women. Maturitas 2005;52:306–318.
2.
Karacam Z, Seker SE: Factors associated with menopausal symptoms and their relationship with the quality of life among Turkish women. Maturitas 2007;58:75–82.
3.
Greene JG: Constructing a standard climacteric scale. Maturitas 1998;29:25–31.
4.
MacGregor EA, Barnes D: Migraine in a specialist menopause clinic. Climacteric 1999;2:218–223.
5.
Hodson J, Thompson J, al-Azzawi F: Headache at menopause and in hormone replacement therapy users. Climacteric 2000;3:119–124.
6.
Kasuga M, Makita K, Ishitani K, et al: Relation between climacteric symptoms and ovarian hypofunction in middle-aged and older Japanese women. Menopause 2004;11:631–638.
7.
Lyndaker C, Hulton L: The influence of age on symptoms of perimenopause. J Obstet Gynecol Neonatal Nurs 2004;33:340–347.
8.
The International Classification of Headache Disorders, ed 2. Cephalalgia 2004;24(suppl 1):9–160.
9.
Lipton RB, Stewart WF: Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43:S6–S10.
10.
Stewart WF, Simon D, Shechter A, Lipton RB: Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995;48:269–280.
11.
Brandes JL: The influence of estrogen on migraine: a systematic review. JAMA 2006;295:1824–1830.
12.
Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M: Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995;15:140–144.
13.
Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993;17:31–37.
14.
Abramson JH, Hopp C, Epstein LM: Migraine and non-migrainous headaches. A community survey in Jerusalem. J Epidemiol Community Health 1980;34:188–193.
15.
Whitty CW, Hockaday JM: Migraine: A follow-up study of 92 patients. Br Med J 1968;1:735–736.
16.
Mattsson P, Svardsudd K, Lundberg PO, Westerberg CE: The prevalence of migraine in women aged 40–74 years: a population-based study. Cephalalgia 2000;20:893–899.
17.
Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH: Migraine prevalence during menopausal transition. Headache 2003;43:470–478.
18.
Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64–69.
19.
Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S: Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008;111:127–136.
20.
Gold EB, Sternfeld B, Kelsey JL, et al: Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol 2000;152:463–473.
21.
Kuh DL, Wadsworth M, Hardy R: Women’s health in midlife: the influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol 1997;104:923–933.
22.
Li C, Borgfeldt C, Samsioe G, Lidfeldt J, Nerbrand C: Background factors influencing somatic and psychological symptoms in middle-age women with different hormonal status. A population-based study of Swedish women. Maturitas 2005;52:306–318.
23.
Mattsson P: Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 2003;43:27–35.
24.
Sueblinvong T, Taechakraichana N, Phupong V: Prevalence of climacteric symptoms according to years after menopause. J Med Assoc Thai 2001;84:1681–1691.
25.
Whitty CW, Hockaday JM: Migraine: A follow-up study of 92 patients. Br Med J 1968;i:735–736.
26.
Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG: A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–358.
27.
Burger HG, Hale GE, Robertson DM, Dennerstein L: A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women’s Midlife Health Project. Hum Reprod Update 2007;13:559–565.
28.
Hunter M, Battersby R, Whitehead M: Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas 1986;8:217–228.
29.
Paulson GW: Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995;173:1734–1741.
30.
Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22:355–365.
31.
MacGregor EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004;3:354–361.
32.
Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD: Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517–1523.
33.
Rousseau ME, Gottlieb SF: Pain at midlife. J Midwifery Womens Health 2004;49:529–538.
34.
Avis NE, Stellato R, Crawford S, et al: Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345–356.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.